EBIT: Income before interest and taxes.
CytomX Therapeutics, Inc. (CTMX) had EBIT of $25.00M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$138.10M |
|
$31.87M |
|
-- |
|
$138.10M |
|
$113.11M |
|
$25.00M |
|
$7.10M |
|
$32.09M |
|
$32.09M |
|
$31.87M |
|
$31.87M |
|
$31.87M |
|
$31.87M |
|
|
EBIT |
$25.00M |
$21.45M |
|
84.44M |
|
84.75M |
|
$0.38 |
|
$0.38 |
|
| Balance Sheet Financials | |
$107.31M |
|
$2.47M |
|
$13.23M |
|
$120.53M |
|
$85.77M |
|
-- |
|
$35.22M |
|
$120.99M |
|
$-0.46M |
|
$-1.99M |
|
$-0.46M |
|
80.10M |
|
| Cash Flow Statement Financials | |
$-86.23M |
|
$99.70M |
|
$7.52M |
|
$18.09M |
|
$39.08M |
|
$20.99M |
|
$7.67M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
18.10% |
|
18.10% |
|
15.53% |
|
23.24% |
|
23.08% |
|
$-86.54M |
|
-- |
|
-- |
|
-- |
|
1.15 |
|
-- |
|
44.51 |
|
8.20 |
|
-6988.32% |
|
-1603.07% |
|
26.44% |
|
-6988.81% |
|
$-0.01 |
|
$-1.02 |
|
$-1.02 |
|